Mifescan 25 Tablet is a prescription-only medication containing Mifepristone, a selective progesterone receptor modulator, in a strength of 25mg per tablet. It is indicated for the termination of intrauterine pregnancy up to 63 days of amenorrhea, as well as for the treatment of uterine fibroids and endometrial hyperplasia. The medication works by binding to progesterone receptors, resulting in the inhibition of progesterone's effects on the uterus and the subsequent induction of uterine contractions. Mifescan 25 Tablet is administered orally and is typically taken as a single dose. It is contraindicated in patients with certain medical conditions, such as liver disease, and is not recommended for use in women who are breastfeeding or have a history of ectopic pregnancy. Common side effects include nausea, vomiting, diarrhea, and menstrual irregularities. The medication should be used under the guidance of a healthcare provider and in accordance with the recommended dosage and administration instructions.